Two HDAC inhibitors, vorinostat (Merck) and romidepsin (Gloucester Pharmaceuticals), have been approved by the US FDA for the treatment of cutaneous T-cell lymphoma, a rare form of non-Hodgkin’s lymphoma that affects the skin [38]. This evidence concerns the gene HDAC9 and primary cutaneous T-cell non-Hodgkin lymphoma.